Artiva Biotherapeutics, Inc.(ARTV)
$3.83+0.06 (+1.59%)
ARTV
Artiva Biotherapeutics, Inc. stock drug pipeline
$3.83
At close:+0.06 (+1.59%)
Want to see ARTV full AI Analyst Report?
Artiva Biotherapeutics, Inc. (ARTV) Drug Pipeline
490 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Allogeneic Nk Cells | Myositis, Scleroderma, Systemic Sclerosis (Ssc), Refractory Rheumatoid Arthritis (Ra), Idiopathic Inflammatory Myopathies (Iims), Rheumatoid Arthritis (Ra, Iim, Sjogren Syndrome, Sjogrens Disease | Phase II | Recruiting | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | May 19, 2025 | ― |
| Cyclophosphamide, Fludarabine, Gcc2005 | Lymphoma, T-Cell | Phase I | Recruiting | Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies | Nov 19, 2024 | ― |
| Rituximab, Cyclophosphamide, Fludarabine, Obinutuzumab, Ab-101 | Lupus Nephritis - Who Class Iii, Lupus Nephritis - Who Class Iv, Sle, Refractory Systemic Lupus Erythematosus | Phase I | Recruiting | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus | Feb 09, 2024 | ― |
| Afm13, Cyclophosphamide, Fludarabine, Interleukin-2, Ab-101 | Peripheral T Cell Lymphoma, Relapsed Or Refractory Hodgkin Lymphoma | Phase II | Terminated | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | May 19, 2023 | ― |
| Cyclophosphamide, Fludarabine, Ab-201 | Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | phase1AndPhase2 | Withdrawn | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | Dec 23, 2022 | ― |
| Rituximab, Bendamustine, Cyclophosphamide, Fludarabine, Interleukin-2, Ab-101 | Non Hodgkin Lymphoma | phase1AndPhase2 | Active Not Recruiting | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Dec 04, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Allogeneic Nk Cells | Phase II | Myositis, Scleroderma, Systemic Sclerosis (Ssc), Refractory Rheumatoid Arthritis (Ra), Idiopathic Inflammatory Myopathies (Iims), Rheumatoid Arthritis (Ra, Iim, Sjogren Syndrome, Sjogrens Disease | Recruiting | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | May 19, 2025 | ― |
| Cyclophosphamide, Fludarabine, Gcc2005 | Phase I | Lymphoma, T-Cell | Recruiting | Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies | Nov 19, 2024 | ― |
| Rituximab, Cyclophosphamide, Fludarabine, Obinutuzumab, Ab-101 | Phase I | Lupus Nephritis - Who Class Iii, Lupus Nephritis - Who Class Iv, Sle, Refractory Systemic Lupus Erythematosus | Recruiting | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus | Feb 09, 2024 | ― |
| Afm13, Cyclophosphamide, Fludarabine, Interleukin-2, Ab-101 | Phase II | Peripheral T Cell Lymphoma, Relapsed Or Refractory Hodgkin Lymphoma | Terminated | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | May 19, 2023 | ― |
| Cyclophosphamide, Fludarabine, Ab-201 | phase1AndPhase2 | Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Withdrawn | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | Dec 23, 2022 | ― |
| Rituximab, Bendamustine, Cyclophosphamide, Fludarabine, Interleukin-2, Ab-101 | phase1AndPhase2 | Non Hodgkin Lymphoma | Active Not Recruiting | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Dec 04, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Artiva Biotherapeutics, Inc. (ARTV) have in its pipeline
Artiva Biotherapeutics, Inc. ARTV is currently developing the following drugs: Allogeneic Nk Cells, Cyclophosphamide, Fludarabine, Gcc2005, Rituximab, Cyclophosphamide, Fludarabine, Obinutuzumab, Ab-101, Afm13, Cyclophosphamide, Fludarabine, Interleukin-2, Ab-101, Cyclophosphamide, Fludarabine, Ab-201, Rituximab, Bendamustine, Cyclophosphamide, Fludarabine, Interleukin-2, Ab-101. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

